KOD Stock Summary and Trading Ideas (Kodiak Sciences | NASDAQ:KOD)

Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.

Kodiak Sciences trades on the NASDAQ stock market under the symbol KOD.

As of May 1, 2026, KOD stock price climbed to $43.95 with 98,416 million shares trading.

KOD has a beta of 3.14, meaning it tends to be more sensitive to market movements. KOD has a correlation of 0.13 to the broad based SPY ETF.

KOD has a market cap of $2.73 billion. This is considered a Mid Cap stock.

In the last 3 years, KOD traded as high as $47.84 and as low as $1.37.

The top ETF exchange traded funds that KOD belongs to (by Net Assets): XBI, VTI, IWM, IBB, VXF.

KOD has outperformed the market in the last year with a price return of +908.0% while the SPY ETF gained +31.7%. KOD has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +93.0% and +8.8%, respectively, while the SPY returned +4.8% and +3.1%, respectively.

KOD support price is $41.32 and resistance is $45.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KOD shares will trade within this expected range on the day.